お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
873206

CAR-T細胞療法の世界市場:シェア・市場規模・業界分析 - 標的抗原・適応症・地域別 2020年~2026年

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2020 - 2026

出版日: | 発行: Polaris Market Research | ページ情報: 英文 108 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円
CAR-T細胞療法の世界市場:シェア・市場規模・業界分析 - 標的抗原・適応症・地域別 2020年~2026年
出版日: 2020年02月01日
発行: Polaris Market Research
ページ情報: 英文 108 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のCAR-T細胞療法市場は、2020年から2026年にかけて34.5%のCAGRで推移し、市場規模は2026年までに89億2,000万米ドルに達すると予測されています。CAR-T細胞療法は、患者自身のT細胞を取り出し、遺伝子技術を応用しがん細胞などを攻撃するように作り替えたT細胞を用いる治療法です。多くの企業はより高いシェアを獲得するためにCAR-T細胞療法への投資を開始しています。

当レポートでは、世界のCAR-T細胞療法市場を調査し、市場の概要、標的抗原・適応症・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、業界動向、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 市場概要と範囲

  • 調査目的と範囲
  • 調査の前提
  • 調査手法
  • 重要点
  • ステークホルダー

第2章 エグゼクティブサマリー

  • 市場の定義
  • 市場セグメンテーション

第3章 CAR-T細胞療法市場の考察

  • CAR-T細胞療法:業界スナップショット
  • エコシステム分析
  • 市場力学
  • ファイブフォース分析
  • PEST分析
  • 業界動向
  • 競合ランキング分析
  • CAR-T細胞の開発タイムライン
  • CAR-T細胞の製造プロセス
  • CAR-T細胞療法の副作用
  • 固形がんの標的抗原
  • CAR-T細胞療法の臨床試験
  • 合併・買収・パートナーシップ・コラボレーション
  • CAR-T細胞療法の新たな革新

第4章 CAR-T細胞療法市場:標的抗原別

  • 市場シェア:標的抗原別(実績値・予測値)
  • CD19/CD22
    • 市場規模(実績値・予測値)
    • 市場規模:地域別(実績値・予測値)
  • BCMA
  • その他 (MUC16、L1CAM、ROR1、EGFRvIII、PSCA、NKR-2、IL13Ra2、LewisY)

第5章 CAR-T細胞療法市場:適応症別

  • 市場規模:適応症別
  • びまん性大細胞型B細胞リンパ腫(DLBCL)
    • 市場規模(実績値・予測値)
    • 市場規模:地域別(実績値・予測値)
  • 急性リンパ芽球性白血病(ALL)
  • 慢性リンパ性白血病(CLL)
  • 多発性骨髄腫(MM)
  • 濾胞性リンパ腫(FL)
  • その他

第6章 CAR-T細胞療法市場:地域別

  • 主な調査結果
  • 米国
    • 市場規模:標的抗原別(実績値・予測値)
    • 市場規模:適応症(実績値・予測値)
  • 欧州
  • 日本
  • その他の地域

第7章 企業プロファイル

  • Amgen Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bluebird Bio
  • Caribou Biosciences, Inc.
  • Celgene Corporation (acquired by Bristol-Myers Squibb)
  • Cellectis
  • Celyad
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Johnson & Johnson
  • Mereck KGaA
  • Nanjing Legend Biotechnology Co., Ltd.
  • ノイルイミューン・バイオテック
  • Novartis International AG
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Servier Laboratories
目次
Product Code: PM1389

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 - 2026" provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients' immune cells to fight cancer. The WBCs (white blood cells) are extracted - reengineered - injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.

According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

Polaris Market research has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region

CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 - 2026)

CD19/CD22

BCMA (B-Cell Maturation Antigen)

Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)

CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 - 2026)

Diffuse Large B-Cell Lymphoma (DLBCL)

Acute Lymphoblastic Leukemia (ALL)

Chronic Lymphocytic Leukemia (CLL)

Multiple Myeloma (MM)

Follicular Lymphoma (FL)

Others

CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 - 2026)

U.S.

Europe

Japan

Rest of the World

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research Methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-aways
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market Definition
  • 2.2. Market Segmentation

3. CAR-T Cell Therapy Market - Premium Insights

  • 3.1. CAR-T Cell Therapy- Industry snapshot
  • 3.2. CAR-T Cell Therapy- Ecosystem analysis
  • 3.3. CAR-T Cell Therapy Market dynamics
    • 3.3.1. CAR-T Cell Therapy- Market Forces
      • 3.3.1.1. CAR-T Cell Therapy Market driver analysis
      • 3.3.1.2. CAR-T Cell Therapy Market restraint/challenges analysis
      • 3.3.1.3. CAR-T Cell Therapy Market opportunity analysis
  • 3.4. Industry analysis - Porter's five force analysis
  • 3.5. CAR-T Cell Therapy Market PEST analysis, 2019
  • 3.6. CAR-T Cell Therapy Industry trends
  • 3.7. Competitive Ranking Analysis
  • 3.8. Timeline of CAR-T Cell Therapy Development
  • 3.9. CAR-T Cell Manufacturing Process
  • 3.10. Side-effects of CAR-T Cell
  • 3.11. Antigens targeting solid tumors
  • 3.12. Clinical trials Landscape for CAR-T
  • 3.13. Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
  • 3.14. New Innovations in CAR-T therapies

4. CAR-T Cell Therapy Market Size and Forecast 2017 - 2026 by Target Antigen

  • 4.1. Key findings
  • 4.2. CD19/CD22
    • 4.2.1. Global CD19/CD22 market estimates & forecast, 2017 - 2026
    • 4.2.2. Global CD19/CD22 market estimates & forecast, by region, 2017 - 2026
  • 4.3. BCMA (B-Cell Maturation Antigen)
    • 4.3.1. Global BCMA market estimates & forecast, 2017 - 2026
    • 4.3.2. Global BCMA market estimates & forecast, by region, 2017 - 2026
  • 4.4. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
    • 4.4.1. Global Other Target Antigen market estimates & forecast, 2017 - 2026
    • 4.4.2. Global Other Target Antigen market estimates & forecast, by region, 2017 - 2026

5. CAR-T Cell Therapy Market Size and Forecast by Indication

  • 5.1. Key findings
  • 5.2. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 5.2.1. Global DLBCL market estimates & forecast, 2017 - 2026
    • 5.2.2. Global DLBCL market estimates & forecast, by region, 2017 - 2026
  • 5.3. Acute Lymphoblastic Leukemia (ALL)
    • 5.3.1. Global ALL market estimates & forecast, 2017 - 2026
    • 5.3.2. Global ALL market estimates & forecast, by region, 2017 - 2026
  • 5.4. Chronic Lymphocytic Leukemia (CLL)
    • 5.4.1. Global CLL market estimates & forecast, 2017 - 2026
    • 5.4.2. Global CLL market estimates & forecast, by region, 2017 - 2026
  • 5.5. Multiple Myeloma (MM)
    • 5.5.1. Global MM market estimates & forecast, 2017 - 2026
    • 5.5.2. Global MM market estimates & forecast, by region, 2017 - 2026
  • 5.6. Follicular Lymphoma (FL)
    • 5.6.1. Global FL market estimates & forecast, 2017 - 2026
    • 5.6.2. Global FL market estimates & forecast, by region, 2017 - 2026
  • 5.7. Others
    • 5.7.1. Global Other indications market estimates & forecast, 2017 - 2026
    • 5.7.2. Global Other indications market estimates & forecast, by region, 2017 - 2026

6. CAR-T Cell Therapy Market Size and Forecast by Regions

  • 6.1. Key findings
  • 6.2. U.S.
    • 6.2.1. U.S. CAR-T Cell Therapy Market by Target Antigen, 2017-2026
    • 6.2.2. U.S. CAR-T Cell Therapy Market by Indication, 2017 - 2026
  • 6.3. Europe
    • 6.3.1. Europe CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
    • 6.3.2. Europe CAR-T Cell Therapy Market by Indication, 2017 - 2026
  • 6.4. Japan
    • 6.4.1. Japan CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
    • 6.4.2. Japan CAR-T Cell Therapy Market by Indication, 2017 - 2026
  • 6.5. Rest of the World
    • 6.5.1. RoW CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
    • 6.5.2. RoW CAR-T Cell Therapy Market by Indication, 2017 - 2026

7. Company Profiles

  • 7.1. Amgen Inc. (US)
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Benchmarking
    • 7.1.4. Recent Developments
  • 7.2. Bellicum Pharmaceuticals, Inc. (US)
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Benchmarking
    • 7.2.4. Recent Developments
  • 7.3. Bluebird Bio (US)
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Benchmarking
    • 7.3.4. Recent Developments
  • 7.4. Caribou Biosciences, Inc. (US)
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Benchmarking
    • 7.4.4. Recent Developments
  • 7.5. Celgene Corporation (US) (acquired by Bristol-Myers Squibb)
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Benchmarking
    • 7.5.4. Recent Developments
  • 7.6. Cellectis (France)
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Benchmarking
    • 7.6.4. Recent Developments
  • 7.7. Celyad (Belgium)
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Benchmarking
    • 7.7.4. Recent Developments
  • 7.8. Gilead Sciences, Inc. (US)
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Benchmarking
    • 7.8.4. Recent Developments
  • 7.9. Intellia Therapeutics (US)
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Benchmarking
    • 7.9.4. Recent Developments
  • 7.10. Johnson & Johnson (US)
    • 7.10.1. Overview
    • 7.10.2. Financials
    • 7.10.3. Product Benchmarking
    • 7.10.4. Recent Developments
  • 7.11. Mereck KGaA (Germany)
    • 7.11.1. Overview
    • 7.11.2. Financials
    • 7.11.3. Product Benchmarking
    • 7.11.4. Recent Developments
  • 7.12. Nanjing Legend Biotechnology Co., Ltd. (China)
    • 7.12.1. Overview
    • 7.12.2. Financials
    • 7.12.3. Product Benchmarking
    • 7.12.4. Recent Developments
  • 7.13. Noile-Immune Biotech (Japan)
    • 7.13.1. Overview
    • 7.13.2. Financials
    • 7.13.3. Product Benchmarking
    • 7.13.4. Recent Developments
  • 7.14. Novartis International AG (Swiss)
    • 7.14.1. Overview
    • 7.14.2. Financials
    • 7.14.3. Product Benchmarking
    • 7.14.4. Recent Developments
  • 7.15. Pfizer Inc. (US)
    • 7.15.1. Overview
    • 7.15.2. Financials
    • 7.15.3. Product Benchmarking
    • 7.15.4. Recent Developments
  • 7.16. Sangamo Therapeutics, Inc. (US)
    • 7.16.1. Overview
    • 7.16.2. Financials
    • 7.16.3. Product Benchmarking
    • 7.16.4. Recent Developments
  • 7.17. Servier Laboratories (France)
    • 7.17.1. Overview
    • 7.17.2. Financials
    • 7.17.3. Product Benchmarking
    • 7.17.4. Recent Developments
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.